Magdalena E. Sobieszczyk

Aaron Diamond AIDS Research Center — United States

Medicine · Health Sciences

45h-index13.5kcitations205works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS Research and Interventions(64), HIV Research and Treatment(55), COVID-19 Clinical Research Studies(47), SARS-CoV-2 and COVID-19 Research(43), HIV/AIDS drug development and treatment(31)

Publications200 total

Associations between gender and solicited adverse events after passive infusion of VRC01 or placebo in HVTN 704/HPTN 085
UNC Libraries·2025Open Access
Novel Criteria for Diagnosing Acute and Early Human Immunodeficiency Virus Infection in a Multinational Study of Early Antiretroviral Therapy Initiation
UNC Libraries·2025Open Access
Is Doxy-PEP Right for Me? Piloting a Novel Patient Decision Aid in an Urban Ambulatory Clinic
AIDS and Behavior·2025
Implementation of Doxy-PEP in a Diverse Sexual Health Program in Northern Manhattan: The Doxy-Care Study
American Journal of Public Health·2025· 1 citedOpen Access
Increased Depression and Anxiety Among Men and Transgender Women Receiving Care at a Sexual Health Clinic in New York City During COVID-19
Open Forum Infectious Diseases·2025Open Access
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial
Science Translational Medicine·2025· 13 citedOpen Access
Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357
Clinical Infectious Diseases·2025· 2 cited
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study
EBioMedicine·2025Open Access
Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data
JAMA Network Open·2025· 4 citedOpen Access
High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)
Annals of Internal Medicine·2025· 9 citedOpen Access
COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials
UNC Libraries·2025Open Access
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
UNC Libraries·2025Open Access
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
BMC Immunology·2025· 3 citedOpen Access
P-938. Percutaneous Mechanical Aspiration in Drug Use Associated-Infective Endocarditis
Open Forum Infectious Diseases·2025Open Access
Predictors, patterns, and correlates of moderate-severe psychological distress among New York City College Students during Waves 2–4 of COVID-19
Scientific Reports·2025· 3 citedOpen Access
Fixed Dosing Versus Weight-Based Dosing of HIV-1 Prophylactic Monoclonal Antibodies in Adults: A Pharmacokinetics Modeling Study
SSRN Electronic Journal·2025Open Access
Brief Report: Associations Between Gender and Solicited Adverse Events After Passive Infusion of VRC01 or Placebo in HVTN 704/HPTN 085
JAIDS Journal of Acquired Immune Deficiency Syndromes·2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
The Lancet HIV·2024· 7 citedOpen Access
Leveraging international stakeholders’ experiences with oral PrEP costs to accelerate implementation of the monthly dapivirine vaginal ring: A qualitative study
Health Research Policy and Systems·2024· 1 citedOpen Access
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
UNC Libraries·2024Open Access
page 1 of 10Next →

Frequent Co-authors

Jason Zucker(14), Michael T. Yin(12), Lihong Liu(10), Yicheng Guo(10), Maple Wang(10), Jian Yu(10), Zizhang Sheng(10), David D. Ho(10), Lawrence Corey(10), Sho Iketani(9), Yaoxing Huang(9), M. Juliana McElrath(9), Peter B. Gilbert(9), Barney S. Graham(8), John R. Mascola(8), Yang Luo(7), Manoj S. Nair(7), Shelly Karuna(7), Georgia D. Tomaras(7), Ian Frank(7)